BDR Pharma agrees to acquire controlling stake in Acme's oral formulations business
BDR Pharma has agreed to acquire a controlling interest in Acme's oral solid formulations business from shareholders led by PAG, strengthening its capabilities in specialist formulations while leaving Acme's sterile injectables operation outside the transaction.
The agreement announced on 9 November 2026 provides for BDR Pharma to acquire a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries, expanding its presence in thyroid medicines, female sex hormone products and general pharmaceutical formulations.
PAG and Acme founder Viral Shah will retain and develop the separate sterile injectables business Immacule Lifesciences, while the financial terms and exact ownership percentage remain undisclosed and the proposed controlling-stake acquisition has not been reported as completed.
Field | Content |
Article Type | Deals |
Acquirer | BDR Pharma |
Target Business | Acme oral solid formulations business |
Target Parent | Acme Formulation |
Selling Shareholders | Existing shareholders led by PAG |
Deal Type | Controlling-stake acquisition agreement |
Announcement Date | 9 November 2026 |
Transaction Status | Agreement announced; completion not confirmed |
Ownership Interest | Controlling stake |
Exact Ownership Percentage | Not disclosed |
Purchase Price | Not disclosed |
Transaction Currency | Not disclosed |
Financing Terms | Not disclosed |
Acquired Business Scope | Oral solid formulations business and relevant subsidiaries |
Manufacturing Focus | Oral solid pharmaceutical formulations |
Therapeutic Capability One | Thyroid medicines |
Therapeutic Capability Two | Female sex hormone products |
Therapeutic Capability Three | General pharmaceutical formulations |
Acquirer Therapeutic Focus | Oncology, critical care and women's healthcare |
Strategic Objective | Expand formulation capabilities and commercial opportunities |
Excluded Business | Immacule Lifesciences |
Excluded Business Specialisation | Sterile injectables |
Retained Business Owners | PAG and Acme founder Viral Shah |
Founder | Viral Shah |
Sterile Injectables Business Status | To remain separately owned and developed |
Geographic Market | India |
New Medicine Approval | No new regulatory approval announced |
What Happened | BDR Pharma agreed to acquire a controlling interest in Acme's oral solid formulations business. |
Why It Matters | The acquisition would strengthen BDR's manufacturing and formulation capabilities across several specialist pharmaceutical categories. |
Strategic Significance | Broadens BDR's oral formulations platform while allowing PAG and Acme's founder to continue developing the separate injectables business. |
Financial Clarification | Neither the purchase price nor the exact controlling ownership percentage was disclosed. |
Transaction Distinction | Proposed controlling-stake acquisition of a defined business rather than a completed acquisition of all Acme operations. |
Key Takeaway | BDR plans to take control of Acme's oral formulations business while Immacule Lifesciences remains outside the transaction. |
What to Watch | Transaction completion, ownership structure, integration, manufacturing investment and portfolio expansion. |
Primary Source | PAG |
Primary Source URL | https://www.pag.com/en/bdr-pharma-to-acquire-a-controlling-stake-in-acme%E2%80%99s-oral-solid-formulations-business-from-pag |
Relevant Date | 9 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言